Biotech Values

[cooldrinkh2o]

<You have to give PBYI management enormous credit for designing this creative adjuvant trial >

I thought they inherited the trial design from Pfizer. Also, I thought the design was due to the tox profile of neratinib--as it was too toxic to be combined with Herceptin in an adjuvant setting.

Someone on the board knows the answer to my next question- is two years of Herceptin better than one year of Herceptin in the adjuvant setting? The only comparisons I am aware of is six months vs one year.